BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers.
BiPar Sciences' lead product candidate, iniparib, the United States Adopted Name (USAN) for the investigational PARP1 inhibitor, BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. Iniparib significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.
Iniparib is being evaluated in multiple Phase 2 and Phase 3 clinical trials in advanced solid tumors, including triple-negative breast cancer. The company also has two additional compounds in pre-clinical development: BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and BSI-302, a novel anti-tubulin therapy
Company Details
- Founded
- -
- Address
- South San Francisco, Ca
- Phone
- 650-635-6050
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bipasciences.com
- Keywords
- Oncology.
- HQ
- South San Francisco, CA
Bipar Sciences Questions
Bipar Sciences's helpline number is 650-635-6050
Bipar Sciences's website is bipasciences.com
Bipar Sciences's LinkedIn profile is https://www.linkedin.com/company/bipar-sciences
Bipar Sciences's industry is
Biotechnology Research
Bipar Sciences's top competitors are
Frontida Biopharm, Inc.,
Yourencore,
Amsc,
Dectris Ltd.,
Processa | Business Process Automation With Siemens Mendix,
Fujifilm Wako Chemicals Usa,
Virginia Department Of Agriculture And Consumer Services,
Rmds Lab,
Hcnc Group,
Biocompare.
Bipar Sciences's categories are Biotechnology Research
Bipar Sciences's founding year is 2004
